Biomaterial Database

How long should we treat porphyric patients? 2000

I Yamamori

UI	MeSH Term	Description	Entries
D011164	Porphyrias	A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues.	Porphyria,Porphyrin Disorder,Disorder, Porphyrin,Disorders, Porphyrin,Porphyrin Disorders
D004334	Drug Administration Schedule	Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.	Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997	Time Factors	Elements of limited time intervals, contributing to particular results or situations.	Time Series,Factor, Time,Time Factor

Related Publications

I Yamamori

How long should we treat?

June 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,

I Yamamori

Osteoporosis: how long should we treat?

December 2008, Current opinion in endocrinology, diabetes, and obesity,

I Yamamori

Hereditary Angioedema: How Long Should We Treat?

November 2016, The American journal of medicine,

I Yamamori

Postanoxic coma: how (long) should we treat?

January 2008, European journal of anaesthesiology. Supplement,

I Yamamori

How long should we treat this infection for?

August 2013, Archives of disease in childhood. Education and practice edition,